GlassScriptPhysician profile
Farooq Hassan
NPI 1598739104
$28,802.31
in general payments reported to CMS, 2019-2025
38 companies · $4,219 in 2025
The $4,219 reported for 2025 was more than what 83% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,921 · 2020: $2,555 · 2021: $4,353 · 2022: $4,287 · 2023: $4,533 · 2024: $4,934 · 2025: $4,219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,464.50 |
| Education | $222.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $5,364.07 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Amgen INC. | $4,708.88 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Abbvie INC. | $4,329.26 | 2019-2025 | |
| Ucb, INC. | $3,520.83 | 2019-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $1,458.36 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,439.72 | 2019-2025 | |
| Lilly USA, LLC | $1,122.35 | 2019-2025 | Taltz |
| Glaxosmithkline, LLC. | $920.53 | 2019-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $853.84 | 2019-2025 | Orencia |
| Astrazeneca Pharmaceuticals LP | $707.48 | 2021-2025 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $624.87 | 2019-2025 | Ofev, Cyltezo |
| Horizon Therapeutics Plc | $490.56 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $382.68 | 2019-2025 | Tremfya |
| Mallinckrodt Hospital Products INC. | $299.43 | 2020-2025 | Acthar |
| Genentech USA, INC. | $280.05 | 2019-2025 | Actemra |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farooq Hassan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.